PHA Pharmagest Interactive SA

EQUASENS: ANNUAL ORDINARY GENERAL MEETING - MEETING NOTICE - ON-LINE AVAILABILITY OF MEETING MATERIALS

EQUASENS: ANNUAL ORDINARY GENERAL MEETING - MEETING NOTICE - ON-LINE AVAILABILITY OF MEETING MATERIALS

Villers-lès-Nancy, 9 June 2023 - 6:00 p.m. (CET)

PRESS RELEASE

ANNUAL ORDINARY GENERAL MEETING

MEETING NOTICE

ON-LINE AVAILABILITY OF MEETING MATERIALS

EQUASENS hereby provides notice to shareholders of the Annual Ordinary General Meeting to be held on Thursday, June 29, 2023 at 5.30 pm at the Company’s registered office located in Villers-lès-Nancy (Technopôle de Nancy-Brabois - 5 Allée de Saint Cloud).

The original French language version of the agenda and the resolutions submitted by the Board of Directors to the Ordinary Annual General Meeting were published in the French publication for legal announcements (Bulletin des Annonces Légales Obligatoires) on 15 May, 2023 ().

The Meeting Notice was published on the June 9, 2023 in the BALO (-officiel.gouv.fr/pages/balo-annonce-unitaire/?q.id=id_annonce:20230609230256669) and in the Official Journal “Les Tablettes Lorraines” including the procedures for participating and voting and the main methods to exercise shareholders’ rights.

Both of these notices are available on the Company’s website: . Translations are also available .

Pursuant to article R. 22-10-23 of the French commercial code, EQUASENS has also made available, since June 8, 2023, all the documents and information prescribed by this article and the voting form on its website - Section Investisseurs, Assemblée Générale tab.

For the purpose of communications between the Company and its shareholders, it is strongly recommended that requests or documents be sent, in priority, by email, to the following address: .

About

Founded more than 35 years ago, Equasens Group, which now has more than 1,200 employees in Europe, is the leading publisher of software solutions for the healthcare industry in terms of the diversity of its business applications and market share.

Equasens Group’s specialised business applications facilitate the day-to-day work of healthcare professionals and their teams, working in private practice, collaborative medical structures or healthcare establishments. The Group also provides comprehensive support to healthcare professionals in the transformation of their profession by developing electronic equipment, digital solutions and healthcare robotics, as well as financing and training adapted to their specific needs.

And reflecting the spirit of its tagline " technology for a more human experience", the Group is a leading provider of interoperability solutions that improve coordination between healthcare professionals, their communications and data exchange resulting in better patient care and a more efficient healthcare system.

Listed on Euronext Paris™ - Compartment A

Indexes: MSCI GLOBAL SMALL CAP - GAÏA Index 2020 - CAC® SMALL and CAC® All-Tradable

Included in the Euronext Tech Leaders segment and the European Rising Tech label

Eligible for the Deferred Settlement Service (“Service à Règlement Différé” - SRD) and equity savings accounts invested in small and mid caps (PEA-PME)

ISIN: FR 0012882389 – Ticker Code: EQS

Get all the news about the Equasens Group and on

CONTACTS

Analyst and Investor Relations:

Chief Administrative and Financial Officer: Frédérique SCHMIDT

Tel. +33 (0)3 83 15 90 67 -

Media Relations:

FIN’EXTENSO - Isabelle APRILE

Tel. +33 (0)6 17 38 61 78 -   

Attachment



EN
09/06/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pharmagest Interactive SA

Arnaud Riverain
  • Arnaud Riverain

EQUASENS (EQS) - CA T1 - La reprise prend forme / Achat - Obj. 71,9 € ...

CA T1 de 57 M€ +6,9% (+5,9% à périmètre constant) / 56,5 M€ attendus ; Apport de Calimed 0,5 M€.

 PRESS RELEASE

Equasens: Q1 revenue at 31 March 2025

Equasens: Q1 revenue at 31 March 2025 Villers-lès-Nancy, 12 May 2025 - 6:00 PM (CET) PRESS RELEASE Q1 revenue at 31 March 2025: €57.0m+ 6.9% growth on a reported basis and + 5.9% like-for-like Q1 2025 REVENUE (€m)2024Reported basis2025Reported basisChange /Reported basisOf which external growthLike-for-like change(organic growth)Equasens Group 53.357.03.76.9%0.53.25.9%Q1 2025 revenue / Division (€m)2024Reported basis2025Reported basisChange /Reported basisOf which external growthLike-for-like change(organic growth)Pharmagest39.842.02.25.5% 2.25.5%Axigate Link7.88.30.45.5% 0.45.5%e-Connec...

 PRESS RELEASE

EQUASENS : Chiffre d’affaires au 31 mars 2025

EQUASENS : Chiffre d’affaires au 31 mars 2025 Villers-lès-Nancy, le 12 mai 2025 - 18h00 (CET) COMMUNIQUE DE PRESSE Chiffre d’affaires au 31 mars 2025 à 57,0 M€+ 6,9% en croissance publiée et + 5,9% en croissance organique CA T1 2025 (M€)Publié 2024Publié 2025Variation/publiéDont Croissances externesVariation/périmètre comparable (croissance organique)Groupe Equasens 53,357,03,76,9%0,53,25,9%CA T1 2025 / Division (M€)Publié 2024Publié 2025Variation/publiéDont Croissances externesVariation/périmètre comparable (croissance organique)Pharmagest39,842,02,25,5% 2,25,5%Axigate Link7,88,30,45,5%...

 PRESS RELEASE

EQUASENS :

EQUASENS : Villers-lès-Nancy, le 30 avril 2025 – 16 :00 (CET) COMMUNIQUE DE PRESSEPour diffusion immédiate Mise à disposition du Document d’Enregistrement Universel 2024 (Euronext Paris™ - Compartiment B - FR 0012882389 –$EQS) annonce que son Document d’Enregistrement Universel 2024 a été déposé auprès de l’Autorité des Marchés Financiers (AMF) en date du 29 avril 2025 sous le numéro n° D.25-0334. Ce document est disponible sur le site Internet de l’AMF, -france.org, ainsi que sur le site Internet d’Equasens, . Les documents suivants, diffusés au titre de l’article 222-3 du Règlement ...

 PRESS RELEASE

Equasens: EXCLUSIVE NEGOTIATIONS INITIATED WITH A FRENCH SOFTWARE EDIT...

Equasens: EXCLUSIVE NEGOTIATIONS INITIATED WITH A FRENCH SOFTWARE EDITOR Villers-lès-Nancy, 30 April 2025 - 8:00 AM (CET) PRESS RELEASE EXCLUSIVE NEGOTIATIONS INITIATED WITH A FRENCH SOFTWARE EDITOR TO ACQUIRE TWO SOFTWARE PUBLISHING BUSINESSES OPERATING IN THE PUBLIC HEALTH SECTOR Project for a targeted acquisition in the public health sector: Acquisition of Novaprove, publisher of the ResUrgences software, Acquisition of the DIS business assets, Strategic reinforcement of Equasens Group's Axigate Link division in this market segment *** (Euronext Paris™ - Compartment B - FR 0...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch